)
Dharini Shah
Senior Director (Cell Therapy, Oncology),
Sanofi
Drug Discovery executive with 17 years of experience building teams in Biotech and Pharma & leading projects in R&D. I am a key scientific contributor and strategic driver of 2 exits (Comet and Tidal Therapeutics), SKYRIZI®, a commercial product for the treatment of psoriasis and FDA-cleared for IBD, Spesolimab FDA cleared for pustular psoriasis. Strategic thinker, an interdisciplinary scientist passionate about patient-centered research, applying immune sciences to discover novel targets, and applying different modalities across immuno-oncology and autoimmune diseases. I am currently leading programs for in vivo reprogramming of immune cells with mRNA therapeutics for hematological malignancies.